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Ammonia is known to be a potent neurotoxin that causes severe negative effects on the
central nervous system. Excessive ammonia levels have been detected in the brain of
patients with neurological disorders such as Alzheimer disease (AD). Therefore, ammonia
could be a factor contributing to the progression of AD. In this review, we provide an
introduction to the toxicity of ammonia and putative ammonia transport proteins. We also
hypothesize how ammonia may be linked to AD. Additionally, we discuss the evidence
that support the hypothesis that ammonia is a key factor contributing to AD progression.
Lastly, we summarize the old and new experimental evidence that focuses on energy
metabolism, mitochondrial function, inflammatory responses, excitatory glutamatergic,
and GABAergic neurotransmission, and memory in support of our ammonia-related
hypotheses of AD.
Keywords: ammonia, ammonia transporters, toxicity, Alzheimer disease, energy metabolism, mitochondrial
dysfunction, glutamatergic, GABAergic
INTRODUCTION
All living organisms produce ammonia as a byproduct of cellular metabolism. At high
concentrations, ammonia is toxic and causes deleterious effects to the cell (Cooper and Plum, 1987).
Effects include disruption of cellular energy metabolism, mitochondrial dysfunction, modulation
of inflammatory responses, and neurotransmission in neurons. Existing evidence suggests that
accumulation of ammonia in the brain affects neuronal function and may lead to several
neurological abnormalities. Therefore, ammonia could be a causative factor for Alzheimer disease
(AD) and may be involved in the progression of the disease. In 1993, Seiler for the first time
published his hypothesis about a linkage between ammonia and AD (Seiler, 1993). However, since
then, few research undertakings have directly shown a pathophysiological role of ammonia within
the AD brain. In this review, toxicity and transport of various forms of ammonia are briefly
described. AD–related factors are also highlighted and then built upon to discuss the contribution
of ammonia to AD.
SOURCES OF BRAIN AMMONIA
In this review, the term “ammonia” refers to two chemical species (NH+4 and NH3) and
when referring to a specific molecular form, “NH+4 ” or “NH3” will be used. In mammalian
brains, ammonia is derived mostly from the metabolism of the putative neurotransmitters
glutamate and aspartate, and monoamines. In the brain, ammonia derives from two main
pathways; endogenous and exogenous sources (Figure 1; Seiler, 1993, 2002; O’Donnell,
1997). Endogenous sources of brain ammonia involve: hydrolysis of proteins; degradation
of amino acids (e.g., glutamine, asparagine, and glycine) and degradation of hexamines;
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FIGURE 1 | Diagrammatic representation of sources, transport and metabolism of ammonia in the brain.
deamination of amino-purines, amino-pyrimidines, and
oxidative deamination of primary amines. One endogenous
source comes from abnormalities in glucose metabolism
which results in excessive ammonia concentrations within
the cerebral cortex (Hoyer et al., 1988). Aside from liver
dysfunction, ammonia also could be generated from the
deficiency of brain metabolism or detoxification processes
resulting from the major reduction in the activity of glutamine
synthesis (Suarez et al., 2002). Another source of brain ammonia
is adenosine-3-monophosphate (AMP) deaminase, which
regulates the purine nucleotides and converts AMP to inosine
monophosphate and ammonia. In 1998, Sims and colleagues
found that the activity of adenosine-3-monophosphate (AMP)
deaminase is approximately 2-folds greater in AD brains
compared with control individuals (Sims et al., 1998). These
outcomes led to the assumption that over-activity of AMP
deaminase could be a source of elevated ammonia levels
during deficient glucose metabolism in AD (Sims et al., 1998).
Further, monoamine oxidase (MAO) could be involved, to
a lower extent, in the process of ammonia production due
to degradation of neurotransmitters and non-transmitter
monoamines.
Exogenous sources produce large quantities of ammonia in
the gastrointestinal tract, resulting from bacterial degradation of
urea and deamination of amino acids (Marcaggi and Coles, 2001).
Urea cycle failure and deficient hepatic urea formation, inborn
errors of metabolism, bacterial infection in the gut are major
causes of accumulation of ammonia in the brain (Figure 2).
Evidence to date indicates that ammonia is a key pathogenetic
factor of hepatic encephalopathy (HE) and a major neurotropic
factor of liver failure (Häussinger and Schliess, 2008; Lemberg
and Fernandez, 2009). Additionally, some studies suggest that
excessive ammonia levels in mammals have been related to
AD due to toxic accumulation of glutamine in astrocytes, what
leads to cell swelling and finally cell death (Butterworth, 2002).
However, evidence for a role for ammonia in the pathology of
AD is still not concrete.
TOXICITY OF AMMONIA
Ammonia is the major end product of cellular amino acid
metabolism (Wright, 1995). Ammonia is a highly toxic material
in animals at even sub-millimolar concentrations (Marcaida
et al., 1992; Britto and Kronzucker, 2002). Ammonia is a weak
base with a pK of 9.2–9.8, depending on the temperature and
salinity of the media (Cameron and Heisler, 1983). In body
fluids with a physiological pH (∼7.4) the major fraction of
ammonia (ca. 99%) appears as NH+4 and the rest appears as
NH3 (Figure 1). Both forms of ammonia, NH3 and NH
+
4 , have
toxic effects by potentially disturbing the pH balance of the
cytoplasm and body fluids (Erickson, 1985). Due to the small
size and uncharged state, NH3, can diffuse down its partial
pressure gradient (1PNH3) across lipid bilayers into acidic
vesicles such as lysosomes and impair the appropriate function
of Golgi vesicles and lysosomal proteases. This occur since NH3
can alter the intraorganelle pH away from the optimal necessary
pH for normal operation (Seglen, 1983). Ammonia formed from
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FIGURE 2 | Scheme diagram representing possible consequences of chronic hyperammonemia, presumed to lead to progressive impairment of
astrocytes and neuronal damage as well as mitochondrial malfunction.
glutamate deamination, where its toxicity results from disruption
of the H+ gradient across the inner membranes of mitochondria.
Due to its relative alkalinity, the mitochondrial pH as compared
to the cytoplasmic pH results in an outwardly directed 1PNH3
from the matrix to the intermitochondrial space. Thus, NH3 exits
the mitochondrial matrix along this gradient and binds to H+ in
the inter-membrane space, thereby eliminating the H+ gradient
necessary for ATP synthesis (Cooper and Plum, 1987). Therefore,
a dropping pH drives oxidative phosphorylation where ammonia
is acting as an H+-gradient-uncoupler (O’Donnell, 1997). In
addition, hydrated NH+4 and K
+ ions have the same ionic
radius of 1.45 Å (Knepper et al., 1989; Weiner and Hamm,
2007), which could result in competition at the K+ binding site
of K+-channels. This competition affects neuronal excitability
and membrane potential in mammalian neurons (Cooper
and Plum, 1987). It has also been demonstrated that high
ammonia concentrations can depolarize hippocampal neurons
(Bosoi and Rose, 2009). Elevated ammonia also causes major
damage in the CNS, including changes in blood-brain barrier
(BBB) morphology (Laursen and Diemer, 1979), modification in
astrocyte and neuron morphology (Gregorios et al., 1985), and
HE (Butterworth, 2002).
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In addition, elevated ammonia levels in mammals have
been related to AD due to toxic accumulation of glutamine
in astrocytes, which leads to cell swelling and ultimately cell
death (Butterworth, 2002). In microglia and astroglioma
cell-lines, ammonia affects major functional activities such
as phagocytosis and endocytosis. In addition, ammonia
modifies the secretion of cytokines and elevates the activity of
lysosomal hydrolases (Atanassov et al., 1994, 1995). Further,
ammonium ions inhibit important enzymes involved in protein
metabolism, such as alpha-ketoglutarate dehydrogenase and
isocitrate dehydrogenase, which ultimately leads to free radical
generation (Cooper and Plum, 1987). Moreover, elevated
ammonia concentration reduces the activity of the antioxidant
enzymes, and results in inhibition of mitochondrial electron
transport chain (ETC) (Murthy et al., 2001). In rat brain it
has been shown that high ammonia concentrations interact
with mitochondria and inhibit complexes I–IV of the ETC
(Veauvy et al., 2002). Marcaida and coworkers found evidence
that ammonia toxicity is mediated by excessive activation of
N-methyl-D-aspartate (NMDA)-type glutamate receptors in
the brain. As a consequence, cerebral ATP is depleted while
intracellular Ca2+ increases with subsequent increases in
extracellular K+, leading to cell death (Marcaida et al., 1992).
Additionally, neurotoxicity is mediated by a direct inhibitory
effect of ammonia on the astrocytic EAAT-1 (GLAST) and
EAAT-2 (GLT-1) transporters, which are responsible for the
removal of glutamate from the neuronal synapse (Knecht
et al., 1997; Norenberg et al., 1997; Chan et al., 2000). In most
species, including mammals, the ammonia concentration of
body fluids is typically low (ca. 50–250 µM) (Cooper and Plum,
1987). Concentrations exceeding 1 mM are usually toxic to
mammalian cells (Hrnjez et al., 1999). Because of its toxicity an
effective ammonia detoxification or excretion system is crucial
to maintain cellular and body fluid ammonia levels within a
tolerable range to ensure normal systemic functions.
AMMONIA TRANSPORTERS
Rhesus Proteins (Rh)
To protect the brain from ammonia-induced stress,
understanding the specific role of ammonia transporters,
which are putatively involved in the ammonia transport system,
is critical. The ammonia-transporting proteins in humans
are the Rhesus (Rh) proteins: RhAG, RhBG, and RhCG. It
has been shown that total ammonia levels in erythrocytes are
greater than three times as compared to plasma ammonia
levels (Huizenga et al., 1994). The RhAG (erythroid- Rh)
complex may play a role in keeping the total blood ammonia
level low by transporting ammonia inside the red blood cells
(RBCs) (Huang et al., 2004). In mammals, RhAG is located in
erythrocytes and erythropoietic tissues (Nakada et al., 2007).
The RhBG and RhCG (Non-erythroid Rh) proteins have been
distributed in various organs such as brain, kidney, liver, and
skin, more specifically in locations where ammonia production
and excretion is crucial (Liu et al., 2000; Weiner and Verlander,
2003). Gene expression of the Rh proteins from the brain
of rainbow trout, Oncorhynchus mykiss, was significantly
up-regulated upon ammonia-induced stress (Nawata and Wood,
2009). This suggests that the brain Rh proteins contribute at least
partially to the ammonia excretion process.
Functional expression studies of vertebrate Rh proteins differ
and are not clear-cut as to the exact molecular species (NH3
or NH+4 ) that is transported. When expressed in HeLa cells
human erythroid RhAG appears to transport both types of
species (Benjelloun et al., 2005). Tracer studies proposed that
NH+4 is transported across the BBB, from plasma to brain, via
Rh proteins (Ott and Larsen, 2004). The physiological role of
human Rh- proteins was revealed by expressing RhCG in yeast
strains deficient in endogenous ammonia transporters (triple-
Mep1; lacking all three ammonium transporters). Growth of
triple-mep1 cells expressing human Rh on a medium, where
ammonia is the only source of nitrogen showed that RhCG
is capable of transporting ammonium in yeast cells (Marini
et al., 2000). However, the debate regarding transport specificity
of members of the Rh family is ongoing. Recently, the X-ray
crystallographic analysis on RhCG revealed that monomers of
Rh proteins contain a hydrophobic pore element, while the
protein form in a trimeric complex promotes the passage of gas
form of ammonia (NH3) (Gruswitz et al., 2010). Furthermore,
topological analyses indicated that the structures of the 12
transmembrane (TM) domains are conserved in all Rh proteins
(Huang and Peng, 2005). Sequence alignment analyses of Rh
proteins among mammals, fish, crustaceans, nematodes and
insects suggested that Rh proteins are phylogenetically related
and most likely share a conserved ammonia transport function
(Weihrauch et al., 2004; Huang and Peng, 2005; Zidi-Yahiaoui
et al., 2009; Adlimoghaddam et al., 2016).
Aquaporins (AQP)
Aquaporins (AQPs) are membrane proteins that operate as
channels for the transport of water. Some members of the
AQP family of proteins can also be permeable to other
molecules such as glycerol, NH3, urea, NO, O2, CO2, H2O2,
and As(OH)3. Ammonia transport capabilities were confirmed
for four members of the mammalian aquaporin family, AQP3,
AQP7, AQP8, and AQP9, when expressed in Xenopus oocytes
(Saparov et al., 2007; Litman et al., 2009). The gene expression
analysis showed that the expression of AQP-4 is downregulated
in the astrocytes of Spf/GFAP-EGEP mice. However, in a rat
model of acute liver failure, the protein expression level of AQP-
4 significantly increased, which appeared to precede the onset of
astrocyte swelling. Therefore, astrocytes may respond to elevated
blood ammonia concentrations by an alteration in expression
levels of AQP-4 (Rao et al., 2010). Moreover, it was shown that
knocking out the AQP-4 gene in cultured astrocytes is capable
of preventing ammonia-induced cell swelling (Rama Rao et al.,
2014).
V-type H+-ATPase (V-ATPase)
Another way to transport ammonia occurs via vacuolar-type
H+-ATPase (V-ATPase) (Weihrauch et al., 2002). Although
the transporter itself is not directly involved in ammonia
transport, pumping of protons via V-ATPase to the outside of
the epithelium (dropping pH) generates an outwardly directed
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1PNH3 which facilitates NH3 excretion across the membrane
either via passive membrane diffusion or potentially via NH3
permeable channels, such as Rhesus proteins (Nawata et al., 2007;
Musa-Aziz et al., 2009; Gruswitz et al., 2010). This transporter
localized at high expression levels in brain tissues, which may
reveal a particular role in neural tissues beyond its housekeeping
roles. For example, in vitro ammonia treatment stimulates the
activity of H+-ATPase in synaptic vesicles of the rat brain
(Albrecht et al., 1994).
Na+/H+ Exchangers (NHE)
Na+/H+ exchangers (NHE) isoforms are widely distributed in
the mammalian CNS. This in turn is leading to the movement
of Na+ down its concentration gradient into the cytosol
through plasma membrane localized NHEs in exchange for H+.
All cells actively regulate their intracellular pH and NHE is
potentially involved in acid-base regulation. For example, NHE-
1 is highly expressed in neurons and astrocytes to contribute
in cellular pH regulation and cell volume (Pizzonia et al.,
1996; Yao et al., 1999; Chesler, 2003). In addition to cellular
pH regulation, NHEs would promote an acidification across
lipid bilayers and thereby assist ammonia trapping as suggested
in the proximal tubule (Hamm and Simon, 1990). However,
whether transporting protons could assist ammonia trapping for
mammalian astrocytes is not completely understood.
Transport of NH+4
The ionic form of ammonia (NH+4 ) cannot diffuse along
biological membranes; however, they can permeate epithelia
across an electrochemical gradient via the paracellular pathway
based on the ion permeability of the tight junctions. Moreover,
since hydrated NH+4 and K
+ have a similar size and ionic
radius (Knepper et al., 1989; Weiner and Hamm, 2007), NH+4
to a certain extent can compete with K+ and replace K+
as a substrate in K+ transporting proteins, such as Na+/K+-
ATPase (NKA), K+-channels, and Na+/K+/2Cl− co-transporters
(NKCC) (Marcaggi and Coles, 2001; Weiner and Hamm, 2007;
Larsen et al., 2014; Adlimoghaddam et al., 2015; Hertz et al.,
2015).
Na+/K+-ATPase (NKA)
Basolaterally localized Na+/K+-ATPase (NKA), hydrolyzes ATP
to pump three Na+ ions from the cytosol out of the cell
while concurrently pumping two K+ into the cell (Skou, 1957).
The NKA creates an electrochemical gradient of Na+ and
also generates a negative membrane potential that is critical
for many transepithelial transport processes. These processes
are in favor of maintaining cellular osmolality and energizing
various sodium dependent transporters such as NKA (Hu and
Kaplan, 2000; Kaplan, 2002). The involvement of the NKA
in ammonia transport processes has been shown in many
species and various tissues, including the mammalian astrocytes.
In addition, enzyme activity measurements from rat astrocyte
cultures revealed that the NKA also accepts NH+4 as a substrate
substituting K+ and is thereby directly involved in the active
transport of NH+4 (i.e., from the body fluids into the cytoplasm;
Chan et al., 2013; Rangroo Thrane et al., 2013). Protein and
mRNA expression analyses from ammonia-induced astrocyte
cultures indicated that NKA was up-regulated in response to
high ammonia concentrations, suggesting an important role of
NKA in an ammonia transport mechanism (Xue et al., 2010).
Additionally, blocking NKA by using a ouabain inhibitor leads to
reduce ammonium-induced astrocytic swelling, suggesting NKA
is involved in ammonia homeostasis and cell swelling (Dai et al.,
2013; Song and Du, 2014).
K+-Channels
K+-channels, due to their ubiquitous cellular presence, are
likely one of the key candidates to mediate transmembrane
NH+4 transport. In accordance with the aforementioned
competition between K+ and NH+4 , it has been suggested
that NH+4 can permeate through the BBB with the possible
participation of barium-inhibitable K+ channel (Ott and
Larsen, 2004). Additionally, it has been demonstrated that
in cultured astrocytes, inward-rectifying K+ channel genes
(Kir4.1 and Kir5.1) significantly downregulated in conditions of
hyperammonemia (Lichter-Konecki et al., 2008). These results
suggest that alteration of K+ channels could either reveal a
protective response by astrocytes to elevated bloodNH+4 levels, or
it is responsive to increased extracellular brain K+ and plasmaK+
concentration. Thus, alteration in brain K+ level could have a key
impact on neuronal activity and network activity during and after
hyperammonemia. More studies will be needed to investigate
details regarding the mechanisms involved in the transport of
ammonia through K+ channel inill be needed to investigate
details brain.
Na+/K+/2Cl− Co-transporter (NKCC)
The basolaterally or apically localized Na+/K+/2Cl− co-
transporter (NKCC) transports Na+, K+, and 2Cl− in an
electroneutral manner. Two isoforms of NKCC (1 and 2) have
been identified in several cells and tissues. In mammals, NKCC1
is located inmany cell types such as astrocytes and neurons, while
NKCC2 is presented mostly in the kidney.
Recent studies indicated that NKCC1 in mammalian brain
tissue and in brain cell cultures accept NH+4 as a substrate,
subtitling K+, which demonstrates the importance of NKCC in
the ammonia transport system in astrocytes. The NKCC1 has
been shown to transport NH+4 in isolated astrocytes (Jayakumar
et al., 2008). Recent studies have also shown that in cultured
astrocyte from rats, the NKCC1 was activated in response to
NH+4 exposure. Thus, increasing NKCC activation was associated
with astrocyte swelling, a process that was blocked by a
NKCC inhibitor (Jayakumar et al., 2008; Rangroo Thrane et al.,
2013). These studies highlight the role of NKCC in ammonia
homeostasis and astrocyte swelling.
THE NECESSITIES OF COMPARATIVE
STUDIES AND NITROGEN TRANSPORT
Overall, dysregulation of the nitrogen transport system
due to ammonia toxicity and any changes in ammonia
transporter expression and function could affect brain
ammonia homeostasis and function, which may lead to
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severe neuronal damage in the AD brain. As mentioned above,
changes in the expression of ammonia transporters most
likely play a critical role in ammonia homeostasis and cell
swelling; however, a possible link between the altered ammonia
transporter function and AD is still missing. Therefore, more
studies will be needed to investigate details regarding the
mechanisms involved in the transport of toxic ammonia in
the AD vs. normal brain. Elucidation of clinical pathological
mechanisms related to the ammonia transport system may
provide common links to the etiology of AD. Together
these insights are crucial for developing therapeutic drugs
to modify dangerous ammonia influxes that cause elevated
systemic ammonia levels and eventually lethal brain damage
in AD.
ALZHEIMER’S DISEASE (AD)
Currently, AD is the most common progressive
neurodegenerative disease in the world (Sperling et al.,
2011). It is clinically characterized by disruption to
synaptic plasticity, learning, memory, and several other
cognitive functions (Albert, 1996). Neuropathologically,
AD is characterized by the development of intracellular
neurofibrillary tangles (NFT) formed from the composition
of hyperphosphorylated tau protein and accumulations of
extracellular senile plaques (SP) that aggregate from the
deposition of amyloid-β (Aβ) (Price and Morris, 1999;
Sperling et al., 2011). Another histological hallmark of
the disease is the unfavorable metabolism of amyloid-
β precursor protein (AβPP) in SP and the subsequent
accumulation of AβPP in damaged axons. The overexpression
of AβPP generates a cascade of events that include
hyperphosphorylated tau that leads to synaptic failure (Ward
et al., 2012).
Besides tau hyperphosphorylation (Grundke-Iqbal et al.,
1986) and Aβ deposition (Hardy and Selkoe, 2002), other
pathological aberrations include: transcriptional dysregulation
(Pastorcic and Das, 2007) modified neuroinflammatory process
(Granic et al., 2009) and astrogliosis (Akude et al., 2011).
The etiology and neuropathogenesis of AD suggest that
this disease is complex and is better thought of as a
multifactorial neurodegenerative disorder involving various
proteins (Carreiras et al., 2013). Regarding causative factors
in AD, various hypotheses have been proposed including
impaired energy metabolism, mitochondrial dysfunction (Hoyer,
1998), alterations in neurotransmitter receptors systems (such
as GABA, glutamate, MAO; Sims et al., 1998; Jones, 2002),
micro-RNA deficiency (Nixon, 2013), cell cycle re-entry (Bonda
et al., 2010), cholinergic deficiency (Pinto et al., 2011),
neuroimmunomodulation (Akude et al., 2011), and deficiency in
calcium homeostasis (Berridge, 2010) to name a few.
Among the neurotoxic agents that have been studied in
relation to the pathology of AD, the effect of ammonia, as a potent
neurotoxin, has received less attention than it deserves. In this
review several hypotheses are mentioned regarding the etiology
of ammonia in AD including deficiency in glycose metabolism,
mitochondrial dysfunction, impairment of glutamatergic and
GABAergic neurotransmission, dysregulation of inflammatory
responses, and memory dysfunction.
IMPAIRED ENERGY METABOLISM AND
MITOCHONDRIA IN AD AND
HYPERAMMONIA CONDITIONS
Glucose is the main source of energy within the brain
and dysfunction of glucose metabolism has critical
pathophysiological consequences. Several studies indicate
a significant reduction in glycolytic process in brains
with dementia (Meier-Ruge et al., 1994; Simpson et al.,
1994; Hoyer, 2000, 2004). The dysregulation of glucose
metabolism has been demonstrated by comparing the
enzymatic activity of glucose transporters (Simpson and Davies,
1994), hexokinase (Marcus and Freedman, 1997), pyruvate
dehydrogenase (PDH) (Bubber et al., 2005) and enzymes of the
tricarboxylic acid (TCA) cycle in AD vs. control individuals
(Kosenko et al., 2014).
High ammonia concentrations lead to elevated content
of astrocytic glutamine with a decrease in glutamate
concentration which causes reduction in the activity of the
malate-asparate shuttle (MAS). As a result of impaired MAS,
the pyruvate/lactate ratio decreases in astrocytes. Unrelated
to MAS activity, high ammonia concentrations in both
astrocytes and neurons can inhibit decarboxylation of alpha-
ketoglutarate in the TCA cycle, which leads to inhibition of PDH
(Hertz and Kala, 2007).
Beside deficiency in glucose metabolism, the functionality
of mitochondria is affected in AD brains. This includes:
increases in reactive oxygen species (ROS) production,
disruption in the balance between mitochondrial fission and
fusion, changes in mitochondria morphology, mitochondrial
enzymatic failure, and a reduced rate of mitochondrial
axonal transport (Figure 2; Zhu et al., 2013; Cadonic et al.,
2015).
Although, it has been hypothesized that mitochondrial
regulation is generally genetically inherent, the activity of
mitochondria could be influenced by other neurotoxic factors
such as ammonia. Several studies indicate that ammonia
compromises various parts of the cellular bioenergetic
machinery. For example, the activity of several ETC enzymes,
mitochondrial cytochrome c oxidase, glutathione peroxidase,
and superoxidase dismutase are significantly reduced in
ammonia-treated brain (Kosenko et al., 1997, 1999, 2004, 2007;
Qureshi et al., 1998; Esteves et al., 2009). Also, activity of
superoxidase, ROS and Poly (ADP-Ribose) polymerase (PARP)
increased in brain mitochondria upon anammonia-induced
stress condition (Kosenko et al., 2003, 2004; Moreira et al.,
2008). Existing evidence indicates that energy metabolism is
compromised in AD and ammonia is involved in the disruption
of energy metabolism (i.e., mitochondrial dysfunction) in
AD. However, more studies are required to obtain a better
understanding of how mitochondria are affected by high
ammonia concentrations, how AD vs. normal mammalian brain
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cells handle energy deficiency, and how these organelles protect
themselves from a massive influx of toxic ammonia into the
brain.
AMMONIA EFFECTS ON EXCITATORY
GLUTAMATERGIC AND GABAERGIC
NEUROTRANSMISSION
One of the crucial roles of astrocytes is to protect neurons against
excitotoxicity by taking up excess ammonia (NH3) and glutamate
(Glu) and converting it into glutamine (Gln) via adenosine
tri-phosphate dependent glutamine synthase (GS). Within the
liver and neurons, Gln is hydrolyzed via phosphate-dependent
glutaminase to Glu and ammonia (NH3) (Zielke et al., 1989;
Smith, 1990).
It has been shown in individuals with HE that there is a lack
of balance between excitatory and inhibitory neurotransmission.
The major inhibition is due to decreased expression of Glu
receptors which leads to reduced glutamatergic tone. Moreover,
the inhibition of glutamate transporters (Glt-1) in HE patients
results in reductions in Glu re-uptake into astrocytes following
excessive extrasynaptic accumulation of Glu (Albrecht and Jones,
1999).
Moreover, abnormal ammonia metabolism in AD brains
correlated with decreases of astrocytic GS activity (Suarez et al.,
2002). Changes in the expression level of GS upon an ammonia-
induced stress condition may alter astroglial morphology
(astrocytosis), which can reflect on neuronal function (Figure 2).
The changes in the regulation of GS suggest that the Glu-Gln
cycle may be differentially impaired in AD. Additionally, the
lower activity of GS is related with the density of extracellular
deposits of Aβ and SP in the cortex of AD brains (Le Prince
et al., 1995). It was demonstrated that Aβ can interact with
GS and induce oxidative inactivation of this enzyme as well as
enhance the neurotoxicity of Aβ. Consistent with these findings,
it is suggested that there is a linkage between impaired ammonia
detoxification (due to alteration in GS activity) and amyloid
plaque formation in AD brains (Aksenov et al., 1997; Robinson,
2000).
Besides the effect of ammonia on glutamatergic tone,
ammonia also could alter the gamma-aminobutyric acid (GABA)
system in the brain. GABA is one of the factors that
mediate inhibitory neurotransmission. For example, excessive
levels of ammonia increase GABA release, which leads to
the enhancement of the GABAergic system in AD. Thus,
neurotransmission imbalances caused by ammonia might be
responsible for cognitive deficits in AD (Seiler, 2002; Rama
Rao et al., 2010). However, the mechanisms by which ammonia
contributes to the manifestations of AD remain poorly defined.
AMMONIA TRIGGERED INFLAMMATORY
RESPONSES IN AD
Elevated brain ammonia is capable of affecting crucial
inflammatory processes causing alterations in the release of
cytokines and inflammatory proteins by microglia, astroglioma,
astrocytes, and neurons (Figure 2). Additionally, increased
levels of ammonia induce apoptosis, which is associated with
neuronal degeneration, via different signaling molecules such as
nuclear factor-kappa B (NF-κB) (Buzanska et al., 2000). NF-kB
is a transcription factor with the critical role in the regulation
of inflammatory responses, innate immunity, apopotosis,
and mitochondrial dysfunction (Barnes and Adcock, 1997;
Henderson et al., 2002; Sinke et al., 2008; Shi et al., 2014). These
include inducible nitric oxide synthase (iNOS), nitric oxide
(NO), NADPH oxidase (NOX), superoxide and peroxynitrite,
phospholipase A2 (PLA2), and cycooxygenase-2 (COX-2), which
have been proven capable of inducing astrocyte swelling. Recent
studies have also shown that ammonia activates iNOS, NOX,
PLA2, and COX-2, and inhibition of aftermentioned enzymes
significantly diminishes astrocyte swelling induced by ammonia.
Additionally, immunohistochemical analysis has shown that
ammonia-treated astrocyte cultures are able to increase NF-κB
activity and astrocyte swelling. Blockage of NF-κB activity
by BAY 11-7082, results in a reduction of ammonia-induced
swelling in cultured astrocytes (Sinke et al., 2008; Rama Rao et al.,
2010; Rao et al., 2010). These findings indicate a critical role of
ammonia in activating NF-κB and ultimately astrocyte swelling.
However, the mechanisms that underlie how NF-κB signaling
pathways contribute to astrocyte swelling are not completely
understood. This lack of understanding offers potential avenues
for further research.
Evidence indicates that activation of inflammatory responses
is a pathological hallmark of AD. Neuroinflammation in AD is
marked by increased activity of inflammatory cytokines such as
IL-6, IL-1β, and TNF-α. Because neuroinflammation is one of
key factors in both AD and the hyperammonia condition, it is
hypothesized that targeting neuroinflammatory mediators such
as NF-κB could provide an effective strategy for the treatment
of neurological abnormalities associated with elevated ammonia
levels.
AMMONIA AND MEMORY
Memory disruption is one of the major neuropathological
hallmarks in AD (Albert, 1996). The elevation of ammonia
concentrations progressively leads to impaired mental status
(cognitive, spatial learning, and memory dysfunctions). In 2000,
Aguilar et al. showed that exposure of rat hippocampal slices to
high ammonia concentrations compromised NMDA receptors,
which subsequently impairs memory or conditioned learning in
the animals (Aguilar et al., 2000). Other possible mechanisms
of the learning deficits produced by high levels of ammonia
most likely involve a reduction of the neuronal glutamate-nitric
oxide (NO)-cyclic GMP pathway. Interestingly, reduction of
NO formation correlated with intellectual dysfunction in AD
dementia patients, but not in those with vascular dementia
(Kosenko et al., 2014).
In addition, it has been suggested that chronic ammonia
exposure affects cognitive function through neurosteroid
metabolism. Ammonia impairs the synthesis of neurosteroids,
which is believed to be involved in memory impairment. Also, it
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has been shown that ammonia impairs long-term potentiation
(LTP) in the hippocampus, which a mechanism is thought
critically involved in memory formation. Ultimately, ammonia
may modulate neurosteroid metabolism via excessive activation
of NMDA receptors and the inhibition of LTP through a GABA
receptor-mediated effect (Izumi et al., 2013).
CONCLUSION
Just over 20 years have passed since the first hypothesis was
published suggesting there might be a link between ammonia
and AD (Seiler, 1993). Since then, very few direct investigations
have been in favor of a pathophysiological role for ammonia in
AD brain. However, since high brain ammonia concentrations
have been detected in AD, characterization of physiological and
molecular mechanisms of the ammonia transport system in brain
cells of AD vs. control will now yield a better understanding of
whether ammonia transport is altered in AD. Gaining knowledge
on nitrogen transport mechanisms and its regulation in AD will
have direct relevance to the medical field.
Although, ammonia is not likely a primary cause of AD, it
acts as a potent neurotoxin affects various biological pathways
such as impairment of energy metabolism, mitochondrial
dysfunction, dysregulation of inflammatory response, and
memory dysfunction. Interestingly, these pathways also
contribute to the generation and/or progression of AD.
Aforementioned factors have also been observed in AD. Thus,
more research is required to investigate the potential linkage
between ammonia toxicity and AD. It is believe that investigating
this potential linkage will greatly assist in developing therapeutic
drugs for modifying dangerous ammonia influxes in AD brain
and the prevention of lethal brain cell damage in AD.
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